135 related articles for article (PubMed ID: 31468568)
21. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
Vázquez GH; Bahji A; Undurraga J; Tondo L; Baldessarini RJ
J Psychopharmacol; 2021 Aug; 35(8):890-900. PubMed ID: 34238049
[TBL] [Abstract][Full Text] [Related]
23. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Thomas RK; Baker G; Lind J; Dursun S
J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
[TBL] [Abstract][Full Text] [Related]
24. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Anand A; Mathew SJ; Sanacora G; Murrough JW; Goes FS; Altinay M; Aloysi AS; Asghar-Ali AA; Barnett BS; Chang LC; Collins KA; Costi S; Iqbal S; Jha MK; Krishnan K; Malone DA; Nikayin S; Nissen SE; Ostroff RB; Reti IM; Wilkinson ST; Wolski K; Hu B
N Engl J Med; 2023 Jun; 388(25):2315-2325. PubMed ID: 37224232
[TBL] [Abstract][Full Text] [Related]
25. Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
George D; Gálvez V; Martin D; Kumar D; Leyden J; Hadzi-Pavlovic D; Harper S; Brodaty H; Glue P; Taylor R; Mitchell PB; Loo CK
Am J Geriatr Psychiatry; 2017 Nov; 25(11):1199-1209. PubMed ID: 28739263
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
27. Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression.
Hassamal S; Spivey M; Pandurangi AK
Clin Neuropharmacol; 2015; 38(5):212-6. PubMed ID: 26366968
[TBL] [Abstract][Full Text] [Related]
28. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
29. Association between depression subtypes and response to repeated-dose intravenous ketamine.
Wang C; Zhou Y; Zheng W; Liu W; Zhan Y; Li H; Chen L; Zhang B; Walter M; Li M; Li MD; Ning Y
Acta Psychiatr Scand; 2019 Nov; 140(5):446-457. PubMed ID: 31483855
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
[TBL] [Abstract][Full Text] [Related]
31. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
Hartberg J; Garrett-Walcott S; De Gioannis A
Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
[TBL] [Abstract][Full Text] [Related]
32. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.
Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ
Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434
[TBL] [Abstract][Full Text] [Related]
33. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP
J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
35. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Ludwig VM; Sauer C; Young AH; Rucker J; Bauer M; Findeis H; Ritter P
CNS Drugs; 2021 Aug; 35(8):881-892. PubMed ID: 34283390
[TBL] [Abstract][Full Text] [Related]
38. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
39. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?
Andrade C
J Clin Psychiatry; 2017 Jul; 78(7):e852-e857. PubMed ID: 28749092
[TBL] [Abstract][Full Text] [Related]
40. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.
Katz RB; Toprak M; Wilkinson ST; Sanacora G; Ostroff R
Gen Hosp Psychiatry; 2018; 54():62-64. PubMed ID: 30100209
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
